Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced an Issue Notification for the Chinese patent 201980010826.7 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”. This patent, developed in collaboration with Syngene International Ltd., an integrated research, development, and manufacturing services company, claims a novel process with a reduced number of synthetic steps from seventeen to six to produce SBP-101 (ivospemin), a lead investigational product. The patent is valid until 2039.
Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela Therapeutics, commented, “This expansion of coverage into China and Asia as a whole, is significant for our patent portfolio and aligns with our global clinical programs. With a shorter synthesis of SBP-101, there are several advantages including a more scalable, efficient, and cost-effective manufacturing process. These benefits are essential for future efforts, as they can potentially reduce production costs and improve the overall competitiveness of SBP-101 in the market.
Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Ltd., said, “We are delighted with the continued success of our longstanding collaboration with Panbela. Our partnership with them dates back to 2013 and since then we have collaborated on multiple projects. In this case, streamlining the production process of an investigational product is a core expertise in our Development Services division. A simpler production process means that commercialization will be easier, and the drug will reach patients more quickly. The protection of SBP-101 production through patents in multiple markets and now in China are significant milestones.”
Dr. Simpson added, “This achievement underscores the Company’s commitment to protecting its intellectual property, advancing it’s products on a global scale, which can potentially lead to a broader market access and increased opportunities for SBP-101's success.”
About our Pipeline
SBP-101 / ivospemin
CPP-1X / eflornithine
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company’s latest Environmental, Social, and Governance (ESG)
Cautionary Statement Regarding Forward-Looking Statements
Continental Breakfast Served - For Diamond, Enterprise, Platinum, Super Pass, Exhibitor/Conference, Speaker, Press Pass Holders
Driving Business with Microsoft Expertise and Integration
Construction Getting Precise with IoT